衰老生物标志物用于鉴定和评估长寿干预措施。

Biomarkers of aging for the identification and evaluation of longevity interventions.

机构信息

Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Genetics, School of Medicine, Stanford University, Stanford, CA, USA; Department of Obstetrics and Gynecology, School of Medicine, Stanford University, Stanford, CA, USA.

European Translational Oncology Prevention and Screening Institute, Universität Innsbruck, Innsbruck, Austria.

出版信息

Cell. 2023 Aug 31;186(18):3758-3775. doi: 10.1016/j.cell.2023.08.003.

Abstract

With the rapid expansion of aging biology research, the identification and evaluation of longevity interventions in humans have become key goals of this field. Biomarkers of aging are critically important tools in achieving these objectives over realistic time frames. However, the current lack of standards and consensus on the properties of a reliable aging biomarker hinders their further development and validation for clinical applications. Here, we advance a framework for the terminology and characterization of biomarkers of aging, including classification and potential clinical use cases. We discuss validation steps and highlight ongoing challenges as potential areas in need of future research. This framework sets the stage for the development of valid biomarkers of aging and their ultimate utilization in clinical trials and practice.

摘要

随着衰老生物学研究的迅速发展,确定和评估人类的长寿干预措施已成为该领域的关键目标。衰老生物标志物是在现实时间范围内实现这些目标的重要工具。然而,目前缺乏关于可靠衰老生物标志物特性的标准和共识,这阻碍了它们在临床应用中的进一步发展和验证。在这里,我们提出了一个衰老生物标志物的术语和特征描述框架,包括分类和潜在的临床应用案例。我们讨论了验证步骤,并强调了当前面临的挑战,这些都是未来研究的潜在领域。这个框架为开发有效的衰老生物标志物及其最终在临床试验和实践中的应用奠定了基础。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索